Results 221 to 230 of about 38,268 (270)

Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment

, 2019
Rachael Guenter, Tolulope A. Aweda, Danilea M. Carmona Matos, Samuel Jang, Jason Whitt, Yi‐Qiang Cheng, Margaret Liu, Herbert Chen, Suzanne E. Lapi, Renata Jaskula‐Sztul   +9 more
openalex   +2 more sources

The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model. [PDF]

PLoS One, 2018
Rylova SN, Stoykow C, Del Pozzo L, Abiraj K, Tamma ML, Kiefer Y, Fani M, Maecke HR.   +7 more
europepmc   +1 more source

A new era in oral treatment for acromegaly with the FDA-approved drug paltusotine. [PDF]

Ann Med Surg (Lond)
Ahmed S, Asghar H, Khalid M.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Somatostatin Receptor 2 Expression in Canine Meningioma

Journal of Comparative Pathology, 2019
The neuropeptide somatostatin (SST) plays an important regulatory role in the proliferation of normal and neoplastic cells. Five subtypes of somatostatin receptors (SSTRs), SSTR1-SSTR5, have been identified in human tumours. The SSTR2 subtype is identified most commonly in meningiomas.
G, Foiani, G, Guelfi, E, Chiaradia, F, Mancini, C, Trivelli, G, Vitellozzi, E, Lepri, M T, Mandara   +7 more
openaire   +2 more sources

Small molecule somatostatin receptor subtype-2 antagonists

Bioorganic & Medicinal Chemistry Letters, 2001
The first potent small molecule sst2 antagonists are reported. Altering known sst2 agonist molecules yielded compounds with high sst2 binding affinity and full antagonist activity. Compound 7a, for example, displaced somatostatin binding to the sst2 receptor with an IC(50)=2.9 nM and antagonized somatostatin action with an IC(50)=29nM.
Hay, Bruce A., Cole, Bridget M., DiCapua, Frank, Kirk, Glen W., Murray, Marianne C., Nardone, Rona A., Pelletier, Dennis J., Ricketts, Anthony P., Robertson, Alan S., Siegel, Todd W.   +9 more
openaire   +3 more sources

High-throughput receptor-binding methods for somatostatin receptor 2

Analytical Biochemistry, 2002
Three high-throughput screening methods for quantitating 125I-SS14 binding to human somatostatin receptor 2 (hSST2) have been developed. Microplate-based separation assays were performed in Packard Unifilter and Millipore Multiscreen plates. A homogeneous ligand-binding assay was developed by employing wheat germ agglutinin (WGA)-coated Flashplates ...
Elizabeth T, Birzin, Susan P, Rohrer
openaire   +2 more sources

Suppression of ANP secretion by somatostatin through somatostatin receptor type 2

Peptides, 2011
Somatostatin is a cyclic-14 amino acid peptide which mainly distributed in digestive system and brain. Somatostatin receptor (SSTR) is a G-protein coupled receptor and all five SSTR subtypes are expressed in cardiomyocytes. The aim of this study was to investigate the effect of somatostatin on atrial natriuretic peptide (ANP) secretion and its ...
Shan, Gao, Young-bin, Oh, Amin, Shah, Woo Hyun, Park, Suhn Hee, Kim   +4 more
openaire   +2 more sources

Evidence for Somatostatin receptor 2 in thyroid tissue

Regulatory Peptides, 2007
Somatostatin receptor scintigraphy has found considerable interest for imaging thyroid tumours. Recently, also therapeutic application of Somatostatin analogues labelled with beta-emitting radionuclides has been suggested as treatment option for thyroid tumours with absent radioiodine uptake.
M, Druckenthaner, C, Schwarzer, C, Ensinger, M, Gabriel, R, Prommegger, G, Riccabona, C, Decristoforo   +6 more
openaire   +2 more sources

2. Somatostatin and dopamine receptors

Tumori Journal, 2010
The discovery of the new properties of SSRs and DRs has led to a renewed interest in agents targeting these receptors and has opened new perspectives for medical treatment of patients with pituitary and neuroendocrine tumors resistant to the “classical”, currently available analogs.
openaire   +1 more source